Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of GLP-1 analogue over 12 weeks before administration of investigational dug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients with HbA1c of ≥7.0% and \<10.5%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug~Exclusion Criteria:~* Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.)~* Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg~* Patients with serious renal or hepatic disease~* Patients with eGFR of \<45 mL/min/1.73 m2~* Patients who are the excessive alcohol addicts~* Patients requiring insulin therapy~* Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (TA-7284) ＋GLP-1 analogue (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).